Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers

An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients

NCT04662931 ·Status: COMPLETED ·Phase: PHASE4

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

NCT06975865 ·Status: RECRUITING ·Phase: PHASE3

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

NCT04657822 ·Status: RECRUITING ·Phase: PHASE4

Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease

NCT06287099 ·Status: NOT_YET_RECRUITING ·Phase: NA

Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study

NCT02090296 ·Status: WITHDRAWN ·Phase: PHASE2

Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease

NCT06287086 ·Status: NOT_YET_RECRUITING ·Phase: NA

Decitabine for High-Risk Sickle Cell Disease

NCT01375608 ·Status: COMPLETED ·Phase: PHASE2

Clinical Study of BRL-101 in Severe SCD

NCT06300723 ·Status: ENROLLING_BY_INVITATION ·Phase: NA

An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults

NCT01178099 ·Status: COMPLETED ·Phase: PHASE1

Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry

NCT06662812 ·Status: COMPLETED

Prasugrel Versus Placebo in Adult Sickle Cell Disease

NCT01167023 ·Status: COMPLETED ·Phase: PHASE2

A Study of IMR-687 in Subjects With Sickle Cell Disease

NCT04474314 ·Status: TERMINATED ·Phase: PHASE2

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT06546670 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

The Effect of Rivaroxaban in Sickle Cell Disease

NCT02072668 ·Status: COMPLETED ·Phase: PHASE2

Genetics and Pain Severity in Sickle Cell Disease

NCT01441141 ·Status: COMPLETED

Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease

NCT03664830 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)

NCT03401112 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

NCT01895361 ·Status: COMPLETED ·Phase: PHASE2

Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients

NCT02212535 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

NCT04819841 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

NCT05904093 ·Status: RECRUITING ·Phase: PHASE1

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

NCT06145282 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Participants

NCT06503458 ·Status: TERMINATED

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

NCT03132324 ·Status: TERMINATED ·Phase: PHASE1

Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia

NCT00004492 ·Status: COMPLETED ·Phase: PHASE1/PHASE2